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API5 induces cisplatin resistance through FGFR
signaling in human cancer cells
Han Sol Jang1,2,3,7, Seon Rang Woo1,2,4,7, Kwon-Ho Song1,2,3,7, Hanbyoul Cho5, Doo Byung Chay5,
Soon-Oh Hong1,2,3, Hyo-Jung Lee1,2,3, Se Jin Oh1,2,3, Joon-Yong Chung6, Jae-Hoon Kim5 and
Tae Woo Kim1,2,3,4
Most tumors frequently undergo initial treatment with a chemotherapeutic agent but ultimately develop resistance, which limits the
success of chemotherapies. As cisplatin exerts a high therapeutic effect in a variety of cancer types, it is often used in diverse
strategies, such as neoadjuvant, adjuvant and combination chemotherapies. However, cisplatin resistance has often manifested
regardless of cancer type, and it represents an unmet clinical need. Since we found that API5 expression was positively correlated
with chemotherapy resistance in several specimens from patients with cervical cancer, we decided to investigate whether API5 is
involved in the development of resistance after chemotherapy and to explore whether targeting API5 or its downstream effectors can
reverse chemo-resistance. For this purpose, cisplatin-resistant cells (CaSki P3 CR) were established using three rounds of in vivo
selection with cisplatin in a xenografted mouse. In the CaSki P3 CR cells, we observed that API5 acted as a chemo-resistant factor
by rendering cancer cells resistant to cisplatin-induced apoptosis. Mechanistic investigations revealed that API5 mediated chemo-
resistance by activating FGFR1 signaling, which led to Bim degradation. Importantly, FGFR1 inhibition using either an siRNA or a
speciﬁc inhibitor disrupted cisplatin resistance in various types of API5high cancer cells in an in vitro cell culture system as well as
in an in vivo xenograft model. Thus, our results demonstrated that API5 promotes chemo-resistance and that targeting either API5 or
its downstream FGFR1 effectors can sensitize chemo-refractory cancers.
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INTRODUCTION
In general, traditional therapies such as surgery, chemotherapy
and radiotherapy are implemented to treat many cancer types.
Among these, chemotherapy is frequently used in diverse
strategies, including neoadjuvant, adjuvant and combination
chemotherapies.1 Many patients with different types of cancers
(for example, cervical, head and neck, non-small cell lung, gastric
and bladder cancer) have been preferentially treated with cisplatin
chemotherapy.2–4 Cisplatin (cis-diaminedichloroplatinum) is a
platinum compound that was discovered in the 1960s and is one
of the most potent chemotherapeutic drugs used for cancer
treatment.5,6 Its mechanism involves DNA binding and the
subsequent activation of multiple signaling pathways to induce
cell cycle arrest and apoptosis. These processes have high efﬁcacy
for treating a variety of cancer types.7–10 However, repeated
treatment with cisplatin frequently results in the acquisition of
resistance to anti-cancer drugs.10–13 This resistance to anti-cancer
drugs such as cisplatin is an important contributor of treatment
failure in many cancers and represents an unmet clinical
need.11,12 Thus, many clinical researchers have begun to develop
new strategies to overcome this chemo-resistance, including
combining platinum-based chemotherapy with molecularly tar-
geted drugs. Indeed, to fulﬁll this unmet clinical need among
cancer patients with cisplatin resistance, studies have tried to
provide deﬁnitive evidence regarding the mechanisms of the
novel drug targets that can be used with cisplatin.
Previously published studies12–18 have shown that among the
numerous mechanisms of cisplatin resistance, it was necessary
to focus on acquired apoptosis inhibition to overcome cisplatin
resistance in a wide variety of cancers. In a previous study, we
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showed that resistance to cytotoxic T lymphocyte-induced
apoptosis in cancer cells after immunotherapies was associated
with upregulation of the anti-apoptotic gene API5.19–23 Further-
more, we discovered that API5 mediates immune resistance by
upregulating the FGFR1/ERK pathway, which regulates the
levels of the pro-apoptotic molecule Bim.19 In addition, another
group reported that depleting API5 was shown to enhance the
cytotoxic effect of chemotherapeutic drugs.24 However, the
precise molecular mechanism of API5 activity remains unclear.
Nevertheless, we predicted that API5 regulation of the EGFR1/
ERK/Bim axis is closely connected to the acquisition of cisplatin
resistance and that it is presumably a critical pathway that could
address an unmet clinical need regarding increased incidence of
resistance after cisplatin treatment in cancer cells. In patients
with cervical cancer, API5 overexpression was closely associated
with tumor progression and overall survival.25 In addition, there
are many reports showing that high levels of API5 were
signiﬁcantly associated not only with tumor stage and grade
but also with the chemo-radiotherapy response, and these levels
were also associated with p-ERK1/2 in a subset of cervical
cancer patients.25,26
Here we predicted that API5 levels are critical for the
acquisition of cisplatin resistance in human cancer patients.
Therefore, in this report, we demonstrated that acquired
resistance after repeated treatments with cisplatin is related
to high levels of API5 expression and downregulation
of the pro-apoptotic molecule Bim via FGFR/ERK signaling
in human cancer cells. We aimed to verify via in vivo
experiments whether blocking the API5 downstream pathway
could be a promising novel strategy for therapeutic
intervention.
MATERIALS AND METHODS
Mice
Five-week-old female nude mice were purchased from Central Lab.
Animal (Seoul, Korea). All mice were maintained and handled
according to a protocol approved by the Korea University Institutional
Animal Care and Use Committee (KUIACUC-2015-282). All animal
procedures were performed in accordance with recommendations for
the proper use and care of laboratory animals.
Cells
CaSki, HeLa and HCT116 cells were commercially obtained from
ATCC (Manassas, VA, USA). CaSki and HeLa cells were grown in
RPMI 1640. HCT116 cells were cultured in Dulbecco’s Modiﬁed Eagle
Medium. All media were supplemented with 10% fetal bovine serum,
1% penicillin and 1% streptomycin, and all cell lines were cultured
at 37 °C in an atmosphere containing 5% CO2.
DNA constructs
The pMSCV-hAPI5 plasmids used in this study have been previously
described.19
siRNA constructs
Speciﬁc small interfering RNAs (siRNAs) for GFP (#SP-2003, control),
API5 (#1006580) and FGFR1 (#100382) were purchased from Bioneer
(Daejeon, Korea). The siRNA sequences are as follows: GFP, (sense)
5′-GCA UCA AGG UGA ACU UCA A-3′ and (antisense)
5′-GCA UCA AGG UGA ACU UCA A-3′; API5, (sense) 5′-
GAC CUA GAA CAG ACC UUC A-3′ and (antisense)
5′-UGA AGG UCU GUU CUA GGU C-3′; and FGFR1, (sense) 5′-
CUC ACU GUG GAG UAU CCA U-3′ and (antisense)
5′-AUG GAU ACU CCA CAG UGA G-3′ The siRNAs were delivered
in vitro into six-well plates at a dose of 200 pmol per well using
Lipofectamine 2000 (Invitrogen, Gaithersburg, MD, USA).
Cisplatin and SSR128129 treatments
CaSki, Hela and HCT116 cells were maintained in their respective
media containing 10% fetal bovine serum at 37 °C with 5% CO2.
For the in vitro treatments, CaSki, Hela and HCT 116 cells were seeded
in six-well plates at 1 × 105 cells per well. When the cells grew to
~ 70% conﬂuence, the control and cisplatin groups were grown
in the presence or absence of 4 μM cisplatin for 24 h. For the
SSR128129 and cisplatin co-treatment groups, CaSki, Hela and
HCT 116 cells were treated with 0.05 μM SSR12819 for 8 h followed
by the addition of 2 ml of fresh medium containing 4 μg ml− 1
cisplatin for 24 h.
Generation of the CaSki P3 CR cancer line
For cisplatin selection, nude mice were subcutaneously inoculated
with 1× 106 CaSki cells per mouse. At 7 days following the
cancer challenge, the mice received cisplatin (Selleckchem,
Huston, TX, USA). This treatment regimen was repeated for three
cycles.
Flow cytometry analysis
The P0, P1, P2, P3, N1, N2 and N3 CaSki cancer cell populations were
harvested by trypsinization, washed and resuspended in phosphate-
buffered saline (PBS). To detect API5 expression, primary antibodies
were incubated for 1 h at 4 °C and rinsed, after which secondary
antibodies were added for 30 min at 4 °C. The primary antibody used
targeted API5 (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
and the secondary antibody was an anti-rabbit IgG labeled with
Alexa 488 (Invitrogen Life Technologies, Carlsbad, CA, USA,
#161314). Data acquisition was performed on a FACSCalibur ﬂow
cytometer (BD Biosciences, San Jose, CA, USA) using CellQuest
Pro software (BD Biosciences).
Western blot analysis
Lysates extracted from a total of 1×105 cells were used to perform the
western blot analysis. Primary antibodies against p-FGFR (Y653/654),
FGFR, p-ERK (T202/Y204) and ERK were purchased from Cell
Signaling (Danvers, MA, USA) and diluted 1:5000. Antibodies against
API5 (1:1000, Santa Cruz Biotechnology) and β-actin (1: 10 000, MBL,
Nagoya, Japan) were used for western blotting, and the appropriate
secondary antibodies were conjugated to horseradish peroxidase. Immu-
noreactive bands were developed using a chemiluminescence ECL
detection system (Elpis Biotech, Daejeon, Korea), and the signals were
detected using a luminescent image analyzer (LAS-4000 Mini, Fujiﬁlm,
Tokyo, Japan). The intensity of the western blot signals was quantiﬁed
using Multi Gauge software (Fujiﬁlm).
Apoptosis analysis
To measure drug sensitivity in a cisplatin selection model using human
cervical cancer cells, CaSki P0, P1, P2 and P3 as well as N1, N2 and N3
cancer cell populations were harvested by trypsinization and washed
once with PBS. After cisplatin selection, the percentage of apoptotic cells
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was determined by staining with an antibody targeting active caspase-3
and performing ﬂow cytometry as previously described.
Cancer treatment experiments
On the day of injection, cancer cells were harvested by trypsinization,
washed once with Opti-MEM (Gibco BRL, Carlsbad, CA, USA) and
resuspended in Opti-MEM to the desired concentration for subcuta-
neous injection. Nude mice were subcutaneously injected with 5×106
CaSki P3 CR cells per mouse. At 12 and 19 days following the challenge,
a thermosensitive chitosan hydrogel (CH)27 containing either
0.05 mg kg−1 of SSR128129E (Selleckchem) or DMSO was injected into
the tumor. Mice were monitored for cancer burden and survival for 35
and 50 days after the initial cancer injections.
Immunohistochemistry
We previously performed immunohistochemistry for API5 in 152
surgically resected cervical carcinoma samples using tissue microarrays
and compared the data with clinicopathological factors, including the
survival rates of patients with cervical cancer.25 The samples were collected
from patients with cervical cancer who were treated at the Gangnam
Severance Hospital between 1996 and 2010. Some of the parafﬁn blocks
were provided by the Korea Gynecologic Cancer Bank through the Bio &
Medical Technology Development Program of the Ministry of Education,
Science and Technology, Korea (NRF-2012M3A9B8021800). The tissue
specimens and medical records were obtained with informed consent
from all included patients and approval of the local research ethics
committee (Seoul, South Korea). To assess API5 staining, two scores were
assigned to each sample: (a) staining intensity (categorized as 0 (absent), 1
(weak), 2 (moderate) or 3 (strong)) and (b) the percentage of positively
stained epithelial cells (scored as 0 (0% positive), 1 (1–25%), 2 (26–50%),
3 (51–75%) and 4 (76–100%)). A histoscore was generated by multiplying
the mean intensity and percent scores (overall score range 0–12). After re-
examining the statistical signiﬁcance between groups susceptible and
resistant to chemoradiation based on previous immunohistochemical data
of API5, we generated new ﬁgures and graphs.
Statistical analysis
All data are representative of at least three separate experiments.
Individual data points were compared using a two-tailed Student’s t-
test. For the IHC data, statistical analysis was performed using SPSS
version 21 (SPSS, Chicago, IL, USA). The Mann–Whitney U-test was
used to compare the protein expression levels between each group.
RESULTS
High levels of API5 correlate with resistance to
chemoradiation therapy in patients with cervical cancer
We previously demonstrated via immunohistochemistry that
API5 protein expression was signiﬁcantly associated with
cervical cancer progression.25 As observed in the previous
report, API5 was exclusively localized to the nucleus of tumor
cells (Figure 1a). We found that API5 expression was positively
correlated with resistance to chemoradiation therapy
(P= 0.004) (Figure 1b). These results indicated that the API5
expression levels were highly correlated with chemo-resistance
in human cervical cancer.
Tumor cells with high levels of API5 are selected by repeated
treatment with cisplatin
Given that API5 has been deﬁned as a negative prognostic
factor in cervical cancer and has been implicated as an inhibitor
of chemoradiation therapy in cervical cancer, we decided to
further examine the role of API5 regarding chemoradiation
resistance. First, to examine the biological role of API5 in the
chemo-resistance of cervical cancer cells, we applied a cisplatin
selection model using a human cervical cancer cell line as
illustrated in Figure 2a. Human cervical cancer cells from the
CaSki line (designated as P0 cells) were treated with cisplatin.
Live cancer cells were recovered as the P1 line. Further rounds
of selection were used to generate the P2 and P3 populations.
In addition, we conﬁrmed that the populations exhibited
sequentially increasing resistance to cisplatin treatment as
demonstrated by the percentage of active caspase-3+ cells.
Strikingly, ~ 20% of the P3 cells survived upon treatment with
cisplatin compared with ~ 3% of the P0 cells (Figure 2b).
On the other hand, the number of surviving cancer cells
from N1 to N3, which were parallel stages without cisplatin
selection, remained constant, and their percentage of
surviving cells were similar to that of P0 cells treated in the
Figure 1 The expression levels of API5 were elevated in human tissues resistant to chemoradiation therapy. (a) Representative
immunohistochemical (IHC) staining images of API5 in susceptible and resistant tissues from women with cervical cancer who underwent
chemoradiation therapy. Negative controls were processed using a mouse immunoglobulin G (IgG) isotype antibody. Boxed regions indicate
high magniﬁcation in the insets (scale bar, 100 μm). (b) Box plot depiction of the IHC data. The IHC score is an index of API5 expression
and was computed based on the intensity and area of positive staining. Chemoradiation-resistant samples presented signiﬁcantly higher
API5 expression than chemoradiation-susceptible samples (Mann–Whitney U-test, P=0.004).
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same manner (Figure 2b). Using these models, we assessed
API5 expression to determine whether the API5 expression
levels were correlated with cisplatin resistance. As a result, we
observed a consistent and gradual increase in API5 expression
from P0 to P3, but there were no changes in the API5
expression levels in the cancer cell populations from N1 to
N3 (Figure 2c). Remarkably, the total level of API5 protein was
eight-fold higher in P3 cells than in P0 cells (Figure 2c). The
overall increase in API5 expression in the P3 line was likely due
to the enrichment of API5high cells as opposed to upregulation
of API5 because the percentage of API5high cells rose from
~5% in the P0 line to ~ 90% in the P3 CR line (Figure 2d).
Thus, these data indicated that repeated cisplatin therapy
may induce drug resistance by enriching the API5high cell
population.
API5 induces downregulation of the apoptotic molecule Bim
via FGFR1–ERK signaling to cause cisplatin resistance in
multiple types of API5-overexpressing human cancers
To examine the molecular basis of enhanced cisplatin resis-
tance in cancer cells following cisplatin selection, we assessed
the expression of a set of pro- and anti-apoptotic molecules
from the P0 and P3 CR populations. The protein levels of Xiap,
Bcl2 and Bclxl (as anti-apoptotic molecules) and of Bad, Bak,
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Bax and Bid (as pro-apoptotic molecules) were comparable
between the CaSki P0 and CaSki P3 CR cell lines
(Supplementary Figure 1a). However, the expression of Bim,
a pro-apoptotic protein, was substantially diminished in CaSki
P3 CR cells (Supplementary Figure 1a). A similar result was
observed in our previous report, which stated that API5
rendered cancer cells resistant to cytotoxic T lymphocyte-
induced apoptosis via downregulation of Bim by activating the
FGFR1 signaling pathway.19 Therefore, we observed the
involvement of FGFR1 signaling in the acquisition of cisplatin
resistance. To assess whether the established cisplatin-resistant
cells trigger the FGFR1 pathway, we evaluated the activation of
FGFR1 and ERK by measuring their respective phosphorylation
levels in CaSki P0 and P3 CR cells. As expected, FGFR1 and
ERK phosphorylation levels were markedly increased in CaSki
P3 CR cells (Figure 3a).
We next investigated whether upregulated API5 levels in
CaSki P3 CR cells activated FGFR1/ERK signaling to promote
cisplatin resistance. We treated CaSki P3 CR cells with siRNA
targeting either API5 (siAPI5) or GFP (siGFP) control and
observed the downstream signaling of FGFR1 as well as the
sensitivity toward cisplatin resistance. The knockdown efﬁ-
ciency was conﬁrmed by western blot analysis (Figure 3b).
Inhibiting API5 expression drastically decreased the phosphor-
ylation of FGFR and ERK by ~ 3- to 5-fold and increased the
protein levels of Bim by approximately eight-fold in the CaSki
P3 CR cells (Figure 3b). Consistent with these changes in the
protein levels, upon cisplatin administration, siAPI5-treated
cells had nearly four-fold more apoptotic cells than the siGFP-
treated cells (Figure 3c). Conversely, we conﬁrmed that
introduction of API5 into CaSki P0 CR cells increased the
phosphorylation levels of FGFR1 and ERK by more than
approximately 7-fold and decreased the Bim protein levels by
10-fold (Figure 3d); furthermore, cisplatin treatment resulted
in nearly 4-fold fewer apoptotic API5-overexpressing cells than
non-transduced cells (Figure 3e). We further conﬁrmed
whether the API5–FGFR1–Bim axis is conserved across
multiple cancers. In a previous report, we proﬁled API5
expression across a variety of human cancer cell lines and
found high levels of API5 in several breast, lung, ovarian and
colon cancer cell lines such as HeLa and HCT116.19 Therefore,
we selected HeLa and HCT116 cells as endogenous API-5high
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cancer cell lines and transfected them with either siAPI5 or
siGFP to examine the downstream FGFR1 signaling and the
changes in chemo-resistance to cisplatin. The knockdown
efﬁciency of API5 in the two cancer cell lines was conﬁrmed
by western blot analysis (Figure 3f). Inhibition of API5
expression drastically decreased the levels of phosphorylated
FGFR and ERK by approximately 5- and 10-fold, respectively,
and increased the Bim protein levels in both HeLa and
HCT116 cells by approximately 10- and 7-fold, respectively
(Figure 3f). Consistent with this, siAPI5-transfected cells
treated with cisplatin had approximately three times more
apoptotic cells than treated siGFP-transfected cells (Figure 3g).
Therefore, these data indicated that API5 conveys resistance to
cancer cells and contributes to their cisplatin-resistant pheno-
type via the FGFR1/ERK/Bim axis.
API5-mediated resistance to cisplatin can overcome
inhibition of the FGFR1 pathway
We would expect that blocking the API5 pathway could be a
promising approach for treating cisplatin-mediated resistant
human cancers. However, there are no pharmacological
inhibitors of API5 available. Therefore, we took note of FGFR1,
a downstream effector of the API5 pathway. As FGFR1
signaling plays an important role in the API5-mediated
resistant phenotypes of cancer cells, we would expect that
inhibiting FGFR1 signaling may be an effective strategy in
cancer cells with API5-mediated cisplatin resistance. To test
this hypothesis, we examined whether API5-mediated cisplatin
resistance can be overcome by treatment with SSR128129E, an
allosteric inhibitor of FGF receptor signaling at nanomolar
concentrations. In API5-overexpressing cells, SSR128129E
treatment drastically decreased the levels of phosphorylated
FGFR1 and ERK by 8- to 10-fold and increased the Bim
protein levels by more than 2-fold (Figure 4a). Consistent with
these changes in the protein levels, in the presence of cisplatin,
there were nearly 5-fold more apoptotic SSR128129E-treated
cells than DMSO-treated cells (Figure 4b).
Then, we conﬁrmed whether these features were mediated
by FGFR1 speciﬁcity during the change in susceptibility to
API5-mediated cisplatin resistance via inhibition of the FGF
receptor by SSR128129E. We treated CaSki P3 CR cells with
siRNA targeting either FGFR (siFGFR) or GFP (siGFP,
control). We observed that administration of siFGFR
decreased the pERK protein levels by approximately 3-fold
and increased the Bim levels by more than 5-fold in the
CaSki P3 CR line (Figure 4c). Consistent with these changes in
the protein levels, in the presence of cisplatin, there were nearly
5-fold more apoptotic siFGFR-treated cells than siGFP-treated
cells (Figure 4d). Thus, our data showed that inhibition of
FGFR1 by SSR128129E represents an attractive strategy to
overcome API5-mediated cisplatin resistance in human cervical
cancer.
To overcome cisplatin resistance, inhibiting the FGFR1
pathway is an efﬁcient approach in multiple types of API5-
overexpressing human cancers with cisplatin resistance
To verify the phenotypic effects of SSR128129E in different types
of API5-overexpressing cancers, we selected three representative
lines, HeLa and HCT116 cells (from patients with cervical and
colon cancer, respectively) as well as CaSki P3 CR cells (which
overexpressed API5 and exhibited a cisplatin-resistant phenotype)
and treated cells with either cisplatin or SSR128129E. As
expected, treatment with SSR128129E inhibited FGFR1 activity
in all the tested cancer cell lines in which FGFR1 signaling was
enhanced by API5, which led to inhibition of ERK activity and an
increase in the Bim protein levels (Figure 5a). In addition,
consistent with these changes in the protein levels, there were 4-
to 9-fold more apoptotic SSR128129E-treated cells than DMSO-
treated cells (Figure 5b). Interestingly, we found a striking
increase in the Bim protein levels after a combination treatment
with cisplatin and SSR128129E than after treatment with
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SSR128129E alone (Figure 5a, line 5). These results parallel the
marked increase in the percentage of apoptotic cells under the
same conditions (Figure 5b, column 4, respectively). Here, we
conﬁrmed that treatment with SSR128129E to target FGFR1
signaling could be a common strategy in human cancers with
API5-mediated cisplatin resistance; moreover, this drug can
sensitize cells and improve the therapeutic effects of conventional
cisplatin treatment for cancer.
In a preclinical tumor model, SSR128129E leads to the
regression of cisplatin-resistant cancer growth
To demonstrate the therapeutic value of the API5 pathway and
its downstream molecular axis in vivo, the efﬁcacy of
SSR128129E was tested in nude mice bearing CaSki P3 CR
cells. As indicated in the schedule described in Figure 6a, mice
received cisplatin along with SSR128129E. Treatment with
SSR128129E elicited a profound therapeutic effect, and when
it was used in combination with cisplatin, the cancer was
virtually undetectable even at 21 days after tumor challenge
(Figure 6b and d). Importantly, 100% of mice that received
both cisplatin and SSR128129E survived, even at 48 days after
tumor challenge, while all the animals in the other groups had
died (Figure 6c). Consistent with the in vitro results, we
observed reduced levels of phosphorylated FGFR1 and ERK
as well as elevated levels of Bim protein in the tumor tissues
from all the SSR128129E-treated mice compared with tumor
tissues from the PBS-treated mice (Figure 6e). In addition, the
overall cytotoxic effect of cisplatin was greater after
SSR128129E treatment relative to that after treatment with
PBS as indicated by the percentage of apoptotic tumor cells
(Figure 6f). Taken together, these data showed that inhibiting
FGFR1 represents a rational applicable strategy for regulating
API5high cisplatin-resistant human cancers.
DISCUSSION
Resistance to anti-cancer drugs is a critical problem in
chemotherapy for many cancers and is a major cause of
treatment failure in patients undergoing chemotherapy. Clini-
cally, a treatment strategy that includes cisplatin among the
anti-cancer drugs is implemented in a variety of cancer
types.2–4,6 Cisplatin has a high risk of drug resistance develop-
ment although it has been shown to have a high
Figure 5 FGFR1 signaling mediates cisplatin resistance in multiple types of human cancer cells that overexpress API5. (a) Western blot
analysis of the expression and activation status of pFGFR, pERK and Bim after treatment of CaSki P3 CR, HeLa and HCT116 cells with
DMSO, SSR128129E or cisplatin. β-actin was included as an internal loading control. The numbers below the blot images indicate the
expression as measured by fold change. (b) Flow cytometry analysis of the percentage of apoptotic (active caspase-3+) cells after treatment
of CaSki P3 CR, HeLa and HCT116 cells with DMSO, SSR128129E or cisplatin. All the graphs represent three independent experiments
performed in triplicate. Error bars represent the s.d.'s from the mean. *Po0.01, **Po0.001, ***Po0.001.
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chemotherapeutic efﬁcacy.2 If researchers are unable to deﬁne
the mechanism of acquired resistance to treatment with
cisplatin, many cancer patients who receive cisplatin treatment
will be at various risks of developing drug resistance. In this
respect, this study showed that the expression pattern in
human cancer cells changed after repeated cisplatin treatments.
Speciﬁcally, in a paper reporting that API5 expression is
correlated with a poor prognosis in patients with cervical
cancer, it was brieﬂy explained that API5 expression is
positively related to resistance to chemo-radiation therapy in
patients with cervical cancer.25 These ﬁndings suggest the
possibility that the effect of chemo-radiation therapy can be
compromised in cervical cancer patients with API5 over-
expression, an observation that can have profound clinical
implications.
Here our study provided further evidence to satisfy an
unmet clinical need. We elucidated the speciﬁc molecular
mechanism for the close correlation between API5
overexpression and acquired resistance to cisplatin treatment.
At ﬁrst, the tumor cell population with high API5 expression
levels steadily increased during the process of establishing a
therapeutic resistance model using cisplatin (Figure 1).
This result indicated that API5-overexpressing tumor cells are
selected by repeated cisplatin treatments and develop resistance to
this drug. There is evidence regarding the intimate relationship
between API5 and cisplatin resistance. In addition, the crucial
API5/FGFR/ERK axis that confers cisplatin resistance provides
important clues suggesting that targeting molecules within the
API5 downstream pathway can help overcome cisplatin
resistance.
API5 contains protein-protein interaction domains such as
HEAT and ARM repeats that are well suited for interactions
with multiple binding partners.28 Thus, discovering an API5
inhibitor using structure-based drug design studies is possible.
However, there are no small-molecule drugs that directly target
API5 to date. Considering this, we took note of an inhibitor of
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API5-mediated FGFR activity, which is a receptor tyrosine
kinase that is part of a major class of drug targets, as a potential
inhibitor of API5 signaling.29–32 In a recent report, the small-
molecule allosteric inhibitor SSR128129E, which blocks FGFR
signaling at nanomolar doses, was identiﬁed,33 and its ther-
apeutic potential has been veriﬁed in immuno-resistant cancer
cells.34 It was determined whether this drug can attenuate the
API5-mediated resistant properties induced by cisplatin in
various types of aggressive cancer cells with high levels of
API5 expression. The results were as predicted—when
SSR128129E was used in combination with cisplatin in
cisplatin-resistant API5high cells, we observed that the
cisplatin-mediated resistant phenotype disappeared. The
observed synergistic effect of the combination treatment with
cisplatin and SSR128129E is shown in Figure 5. This phenom-
enon may ultimately be driven by a dramatic increase in caspase
3 and Bim levels. Several studies have shown that cisplatin
sensitivity is mediated by either Bim or caspase 3 regulation.35,36
Thus, our results can be interpreted as a convergence of necrotic
features via accumulation of cisplatin-induced apoptotic signals
in cells with increased sensitivity to cisplatin via inhibition of
FGFR signaling by SSR128129E.
Clinically, a therapeutic strategy with cisplatin that is
effective against multiple types of cancers is necessary to
minimize cisplatin resistance. In our study, we also conducted
in vivo experiments to verify the potential of clinical application
of this novel therapeutic strategy. We conﬁrmed that
SSR128129E signiﬁcantly increased the therapeutic efﬁcacy in
an established xenograft mouse model using cisplatin-resistant
human cancer cells when SSR128129E was used in combina-
tion with cisplatin. Thus, we consider it appropriate that during
cisplatin-based chemotherapy, FGFR-targeted strategies are
useful to treat refractory cancers as well as cisplatin-resistant
cancers with high levels of API5 expression.
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